VANCOUVER, Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully
integrated, cannabinoid-based biopharmaceutical company that
leverages its proprietary platform technologies to develop novel
therapeutics for the treatment of diseases with high unmet medical
needs, today announced that it has filed a Patent Cooperation
Treaty ("PCT") application pertaining to the Company's INM-405
program and other unique compositions as cannabinoid-based topical
therapies for the treatment of pain, which is an important step in
protecting the Company's intellectual and commercial
property. The patent application, entitled "Methods and
Composition for the Treatment of Pain with Cannabinoids" is
designed to provide protection of the Company's INM-405 program in
over 150 different countries including the United States and claims a priority date
from September 22, 2017
(PCT/CA202018/051194).
Dr. Eric Hsu, Ph.D., InMed's Vice
President of Preclinical Research and Development commented, "While
there are numerous pharmaceutical products to treat both acute and
chronic pain, the increase in the number of prescriptions for the
opioid class of products (oxycodone, hydrocodone, morphine,
methadone, fentanyl, etc.) has led to concerns as these products
can be highly addictive and have damaging side effects, including
death." According to the United States Centers for Disease Control
and Prevention, since 1999, the number of overdose deaths involving
opioids (including prescription opioids and heroin) quadrupled, as
have the number of prescriptions for opioids, yet there has been no
increase in the amount of pain reported in the general
population. Thus, there is a need to find alternative
treatments for chronic and severe pain that are non-addictive and
have limited side effects. "InMed is researching the potential of
non-THC (THC is a psychoactive ingredient in cannabis) cannabinoids
to treat pain using a proprietary topical formulation," Dr. Hsu
continued.
"There remains a significant need in the field of analgesia for
a product that can treat pain via a topical route of
administration, which would reduce systemic exposure and any
associated side effects," said Dr. Sazzad
Hossain, Chief Scientific Officer of InMed Pharmaceuticals
and a co-inventor on the patent. "InMed's focus on non-THC
cannabinoids further reduces concerns regarding addiction, a key
concern in pain management."
InMed's study results were published in the European Journal of
Pain in July 2017 and highlighted the
topical application of THC to successfully treat peripheral
pain. The foundation of this patent is the unreported data on
non-THC cannabinoids and their ability to modulate pain. The
patent cites a range of cannabinoids, alone or in combination,
applied topically to treat various types of pain – muscle, nerve,
arthritis-induced joint pain, etc.
The PCT is an international patent law treaty, which provides a
unified procedure for filing patent applications to protect
inventions in each of its member states. There are 151 member
countries within the PCT, enabling near-global patent coverage
through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New
Zealand, China,
Brazil, Russia, India, as well as many others.
About InMed:
InMed is a pre-clinical stage
biopharmaceutical company that specializes in developing novel
therapies through the research and development into the extensive
pharmacology of cannabinoids coupled with innovative drug delivery
systems. InMed's proprietary bioinformatics database drug/disease
targeting tool, cannabinoid biosynthesis technology and drug
development pipeline are the fundamental value drivers of the
Company. For more information, visit www.inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: developing novel therapeutics for the
treatment of diseases with high unmet medical needs; a PCT filing
providing intellectual and commercial protection for the Company's
unique compositions as cannabinoid-based topical therapies for the
treatment of pain; and the expected fundamental value drivers of
the Company.
With respect to the forward-looking information contained in
this news release, InMed has made numerous assumptions regarding,
among other things: the approval and effectiveness of patent
protection; continued and timely positive preclinical and clinical
efficacy data; the speed of regulatory approvals; demand for
InMed's products; and continued economic and market
stability. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk factors which
could cause InMed's actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include,
among others: InMed may not be able to obtain intellectual and
commercial protection for its technologies; preclinical and
clinical testing may not produce the desired results on a timely
basis, or at all; regulatory applications may not be approved on a
timely basis, or at all; suitable partners may not be located;
economic or market conditions may worsen; and InMed's proprietary
bioinformatics database drug/disease targeting tool, cannabinoid
biosynthesis technology and drug development pipeline may not
deliver the expected level of results nor become the fundamental
value drivers of the Company. A more complete discussion of
the risks and uncertainties facing InMed is disclosed in InMed's
most recent Annual Information Form and other continuous disclosure
filed with Canadian securities regulatory authorities on SEDAR at
www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-files-pct-patent-application-for-the-treatment-of-pain-with-cannabinoids-300718203.html
SOURCE InMed Pharmaceuticals Inc.